Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy

Mingfeng Lee1 · Hitoshi Suzuki1 · Rina Kato1 · Yusuke Fukao1 · Maiko Nakayama1 · Toshiki Kano1 · Yuko Makita1 · Yusuke Suzuki1

Received: 14 February 2020 / Accepted: 2 July 2020 / Published online: 16 July 2020 © The Author(s) 2020

Abstract
In several cases with IgA nephropathy (IgAN), differential diagnosis is difficult due to the complication with other systemic diseases which can induce secondary IgAN. Recently, we demonstrated that immunostaining with galactose-deficient IgA1-specific monoclonal antibody (KM55 mAb) specifically showed positive in primary IgAN cases. Here, we report four cases which we could make definitive diagnosis by immunohistological analysis using KM55 mAb. The underlying systemic diseases are rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), hepatitis C (HCV) and Crohn’s disease (CD). Renal pathological findings in the four cases revealed mesangial proliferative glomerulonephritis with IgA and C3 deposits. Immunostaining with KM55 mAb was positive for three cases complicated with RA, SLE and CD, respectively. Thus, these three cases were diagnosed as primary IgAN and treated with tonsillectomy and steroid pulse therapy. These three cases finally achieved clinical remission. On the other hand, the case with HCV showed negative for KM55. Finally, we diagnosed as HCV-related nephropathy and successfully treated by antiviral agents. These cases suggested KM55 mAb is a strong tool to differentiate primary IgAN from secondary IgAN.

Keywords IgA nephropathy · Galactose-deficient IgA1 · KM55 · IgA deposition

Introduction
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is defined as primary glomerulonephritis with predominant glomerular IgA deposition. However, glomerular IgA deposition is found not only in IgAN but also in other systemic diseases like gastrointestinal and liver diseases, autoimmune disorders, neoplasia and infections [1]. It is important to differentiate primary IgAN from secondary IgAN, because therapeutic strategy is different depending on the underlying primary disease. However, it is not easy to distinguishing primary IgAN from secondary IgAN, if the patient has comorbidities which could induce secondary IgAN. Previous studies have demonstrated that galactose-deficient IgA1 (Gd-IgA1) is specifically involved in the pathogenesis of primary IgAN [2, 3]. Recently, the method of measuring serum levels of Gd-IgA1 using monoclonal antibody against Gd-IgA1 (KM55 mAb) has been established [4]. Besides, we reported that KM55 mAb could detect Gd-IgA1 deposition in glomeruli in the cases of primary IgAN, but not in other renal diseases [5]. Thus, histological analysis using KM55 mAb may be a strong tool for differentiating primary IgAN from secondary IgAN. Here, we show 4 cases which we could make definitive diagnosis by immunostaining with KM55 mAb.

Case reports

Case 1
A 44-year-old woman had presented hematuria and proteinuria from 7 years ago. She was admitted to perform renal biopsy in our hospital. Besides, she has showed PIP joints pain for several years. Both rheumatoid factor (RF)
and anti-cyclic citrullinated peptide antibody (anti-CCP) showed positive. Thus, rheumatoid arthritis (RA) was diagnosed by rheumatologist.

Blood examination showed Cr 0.43 mg/dl, eGFR 121.8 mL/min/1.73 m², IgG 1429 mg/dl, IgA 653 mg/dl, C3 72 mg/dl, RF 734.4 IU/ml, anti-CCP-Ab 6.2 IU/ml. Antinuclear antibodies (ANA), myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA), proteinase3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA), anti-glomerular basement membrane antibodies (anti-GBM), and cryoglobulins were negative. Urinalysis showed urine protein–creatinine ratios (UPCR) 2.4 g/gCr, urinary red blood cells (U-RBC) 11–15/high-power field (HPF).

Light microscopic finding (LM) revealed mesangial cell proliferation and increase of mesangial matrix as well as endocapillary proliferation. Immunofluorescence analysis (IF) revealed mesangial deposition of IgA and C3. Mesangial and capillary deposition of IgG and IgM also noted. (Fig. 1).

Based on the pathological findings, we diagnosed as IgAN. To exclude secondary IgAN caused by RA, immunostaining with KM55 mAb was performed. Finally, we diagnosed as primary IgAN due to positive staining of KM55 mAb colocalized with IgA deposit area (Fig. 2).

According to the diagnosis of primary IgAN, tonsillectomy with steroid pulse (TSP) therapy was performed. Urinary abnormalities has been gradually improved and achieved clinical remission (CR) afterward (Fig. 3). CR defined as three consecutive negative results over a 6-month period in urinary occult blood tests; urinary sediment red blood cell count of < 5/HPF; and urinary protein of < 0.3 g/day [6]. After TSP therapy, serum levels of IgA and Gd-IgA1 significantly decreased (Table 1).

Clinical symptoms of RA initially getting better by steroid therapy. However, after tapering steroid dosage, PIP joints pain has gradually getting worse without relapse of urinary abnormalities. Thus, treatment with methotrexate (MTX) was started after finishing steroid therapy. Currently, the disease activity of RA has been under control with MTX treatment and urinary findings have also maintained remission.

**Case 2**

A 42-year-old woman who was diagnosed as systemic lupus erythematosus (SLE) when she was 39 years old with the
findings of polyarthritis, positive for ANA (1:640, homogeneous and speckled pattern) and anti-ds-DNA Ab, lymphocytopenia, and proteinuria (0.5–1.0 g/gCr). She had been followed by rheumatologist without any treatment. However, proteinuria and hematuria had been persisted. Thus, a renal biopsy was performed for definitive diagnosis.

Blood examination showed Cr 0.35 mg/dl, eGFR 177.8 mL/min/1.73m², IgG 1214 mg/dl, IgA 282 mg/dl, C3 103 mg/dl. ANA, anti-ds-DNA, anti-SS-A, anti-SS-B, RF, and anti-CCP were positive. MPO-ANCA, PR3-ANCA, anti-GBM, and cryoglobulins were negative. Urinalysis showed UPCR 0.64 g/gCr and U-RBC > 50/HPF.

LM revealed mild mesangial cell proliferation and increase of mesangial matrix. IF showed mesangial deposition of IgA and C3, but negative for C1q that is atypical for lupus nephritis (Fig. 1). Based on the pathological findings, we could not diagnose definitively IgAN or lupus nephritis. Then, immunostaining with KM55 mAb was performed and showed its positive staining colocalized with IgA (Fig. 2). Finally, we diagnosed as primary IgAN. After TSP therapy, urinary abnormalities have been gradually improved and achieved CR (Fig. 3). Moreover, level of Gd-IgA1 significantly decreased (Table 1).

Disease activity of SLE had been relatively stable during steroid usage. However, after discontinuation of steroid treatment, polyarthritis exacerbated and serum level of anti-ds-DNA Ab gradually elevated. She has been followed by rheumatologist. Currently, induction of additional immunosuppression therapy is considered. Both proteinuria and hematuria have been able to maintain remission.
Fig. 3 Clinical courses of cases 1–4. *mPSL* methylprednisolone, *PSL* prednisolone, *MTX* methotrexate, *QD* once daily, *QOD* every other day, *QW* once a week, *eGFR* estimated glomerular filtration rate [mL/min/1.73 m²], *UPCR* urine protein–creatinine ratio [g/gCr], *U-RBC* urinary red blood cells, *HPF* high-power field, *SVR* sustained virological response.
Case 3

A 63-year-old man had presented with proteinuria (0.5–1.0 g/gCr) from 7 years ago. Proteinuria progressed to around 5.0 g/gCr. A renal biopsy was performed for definitive diagnosis. Besides, he had hepatitis C (HCV) without any anti-viral treatment.

Blood examination showed Cr 0.74 mg/dl, eGFR 114.3 mL/min/1.73 m², IgG 1905 mg/dl, IgA 338 mg/dl, C3 120 mg/dl. ANA, RF, MPO-ANCA, PR3-ANCA, anti-GBM and cryoglobulins were negative. HCV-RNA showed as 5.6 LogIU/mL. HCV subtyping showed type 1b. Urinalysis showed UPCR 3.6 g/gCr and U-RBC showed 1–4/HPF. Serum level of Gd-IgA1 was low, compared with cases 1, 2 and 4 (Table 1).

LM revealed mesangial cell proliferation and increase of mesangial matrix as well as endocapillary proliferation. IF showed slightly positive for IgA and C3 in mesangial area (Fig. 1). IgG also showed weakly positive in capillary area. For the presence of active inflammatory lesions, such as endocapillary proliferation, we diagnosed as active IgAN with massive proteinuria.

Initially, we considered to arrange steroid pulse therapy to treat acute lesions. However, for the complication of HCV, steroid therapy would be the risk of its activation. We decided to administer oral steroid therapy instead of steroid pulse therapy after discussing with gastroenterologist.

After informed consent, we started steroid therapy with close monitoring of liver function. However, improvement of proteinuria was limited and the liver function gradually getting worse. Thus, we stopped steroid therapy and performed immunostaining with KM55 mAb and showed its positive staining colocalized with IgA (Fig. 2). Finally, we diagnosed as HCV-RN. After TSP therapy, urinary abnormalities have been gradually improved and achieved CR (Fig. 3). Furthermore, serum levels of IgA and Gd-IgA1 significantly decreased (Table 1).

Discussion

There are increasing evidences that Gd-IgA1 play a pivotal role in the pathogenesis of IgAN [7]. Elevations of serum Gd-IgA1 levels and mesangial deposition of Gd-IgA1 were reported in patients with IgAN [3, 5]. Multi-hit hypothesis which includes (Hit 1) production of Gd-IgA1, (Hit 2) IgG or IgA autoantibodies that recognize Gd-IgA1, (Hit 3) their subsequent immune complexes formation and (Hit 4) glomerular deposition was advocated as the most probable pathogenesis of IgAN [2].

Gd-IgA1 is thought to be induced by abnormal mucosal immune responses mainly at the upper respiratory tract including tonsil [8]. In fact, clinical efficacy of tonsillectomy in patients with IgAN has been reported by meta-analysis [9] and recent large retrospective cohort study with propensity score matching [10]. Besides, our group also reported decrease of serum level of Gd-IgA1 just after tonsillectomy associated with the improvement of hematuria [11].

Secondary IgAN is thought to be containing a wide disease spectrum [1]. In the clinical settings, secondary IgAN should be taken into account when systemic comorbidities exist. However, differential diagnosis of primary IgAN from secondary IgAN is not easy, because there are no specific histological features to distinguish them. Secondary IgAN

Table 1 Serum levels of IgA, galactose-deficient IgA1 (Gd-IgA1), and Gd-IgA1/IgA ratio before and after tonsillectomy with steroid pulse (TSP) therapy (in cases 1, 2 and 4) and serum levels of IgA, Gd-IgA1 and Gd-IgA1/IgA ratio at diagnosis (in case 3)

|            | IgA (mg/dl) | Gd-IgA1 (ng/ml) | Gd-IgA1/IgA |
|------------|-------------|----------------|-------------|
| Case 1 (Before TSP) | 653         | 8542.2         | 13.1        |
| Case 1 (After TSP)  | 388         | 4746.8         | 12.2        |
| Case 2 (Before TSP) | 282         | 7277.0         | 25.8        |
| Case 2 (After TSP)  | 258         | 4911.5         | 19.0        |
| Case 3 (At diagnosis) | 338         | 3164.2         | 9.4         |
| Case 4 (Before TSP) | 502         | 8570.6         | 17.1        |
| Case 4 (After TSP)  | 323         | 5063.3         | 15.7        |
can be diagnosed only by the effectiveness of treating underlying systemic comorbidities. At least, tonsillectomy do not improve secondary IgAN. Whether secondary IgAN shares the common pathogenic process with primary IgAN or not is still unclear and needs further investigation.

According to the previous report, glomerular Gd-IgA1 was specifically detected in IgAN but not in the other types of glomerular diseases [5]. Thus, if Gd-IgA1 involvement is proved by immunohistochemical analysis with KM55 mAb, abnormal mucosal immune response might be related to the pathogenic process, and tonsillectomy might be useful for disease control.

In the present cases, the case with RA, SLE and CD (cases 1, 2, and 4) showed positive for KM55 mAb and no correlation between the disease activity of systemic disease and urinary abnormalities. Thus, we diagnosed as primary IgAN. Those three cases showed improvement of urinary abnormalities by TSP therapy. To demonstrate that TSP therapy improved mesangial inflammation caused by Gd-IgA1 deposition diagnosed by KM55 immunostaining, we measured the level of Gd-IgA1 in all cases by KM55 enzyme-linked immunosorbent assay (ELISA) and showed in Table 1. It is clearly indicated that serum levels of IgA, Gd-IgA1 and Gd-IgA1/IgA ratio decreased by TSP therapy. On the other hand, the case with HCV (case 3) showed negative for KM55 mAb. Finally, we diagnosed as HCV-RN. This case showed improvement of urinary abnormalities with anti-viral therapy. All cases successfully achieved remission. Thus, immunohistochemical analysis of KM55 mAb can tell us whether Gd-IgA1 is involved in the pathogenesis or not and even help us to determine therapeutic strategy.

Most of the patients with IgAN show slowly progressive clinical course. Thus, we suggest physicians to treat the comorbidity first, if its activity was severe, even if glomerular Gd-IgA1 showed positive [5]. However, the possibility of KM55-positive secondary IgAN cannot be totally excluded, because IL-6 and IL-4 accentuated galactose deficiency of IgA1 during mucosal infections [12]. Further investigations to elucidate glomerular Gd-IgA1 in case with IgAN accompanied by comorbidities are necessary.

In conclusion, present cases suggested that immunohistochemical analysis using KM55 mAb is a strong tool for differentiation of primary IgAN from secondary IgAN, and enables us to provide appropriate treatment individually.

Acknowledgment This study was supported in part by a Grant-in-Aid for Intractable Renal Diseases Research, Research on rare and intractable diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan.

Compliance with ethical standards

Conflict of interest All the authors declared no competing interests.

Human and animal rights This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent Informed consent was obtained from the patient described in the present case.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018;94:674–81.
2. Suzuki H. Biomarkers for IgA nephropathy on the basis of multipathogenesis. Clin Exp Nephrol. 2019;23:26–31.
3. Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, Iseri K, Sugiyama M, Iyoda M, Shibata T. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. PLoS ONE. 2018;13:e0206865.
4. Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015;30:1315–16.
5. Suzuki H, Yasutake J, Makita Y, Tanbo T, Yanagawa H, Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yamada K, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Matsuzaki K, Horikoshi S, Novak J, Tomino Y. Changes in nephrotic potential of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucus immune system. Adv Otorhinolaryngol. 2011;72:60–3.
6. Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Koh T, Kawamura T, Tomino Y, Matsu S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014;18:481–6.
7. Novak J, Buljan MA, Mestechy J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol. 2012;34:365–82.
8. Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Tomino Y, Gharavi AG. Cytokines alter IgA1 glycosylation and IgA1 vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93:700–5.
9. Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Koh T, Kawamura T, Tomino Y, Matsu S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014;18:481–6.
10. Hirano K, Suzuki Y, Yasuda T, Nishikawa M, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsu S, Kawasaki T, Suzuki S. Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open. 2020;2:e194772.
11. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS ONE. 2014;9:e89707.
12. Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAC-II enzymes. J Biol Chem. 2014;289:5330–9.